This is a preview of subscription content, log in via an institution to check access.
Notes
incremental cost-effectiveness ratio
References
Yeung K, et al. Cost-Utility Analysis of Enzalutamide Versus Abiraterone for the Treatment of Docetaxel Refractory Metastatic Castrate Resistant Prostate Cancer. 18th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PCN86, 18 May 2013.
Persson U, et al. Cost Effectiveness Analysis of Abiraterone Acetate as Treatment for Metastatic Castration Resistant Prostate Cancer after Failure of Docetaxel Using Data from Real Life Treatment Praxis in Sweden. 18th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PCN40, 18 May 2013.
Joulain F, et al. Cabazitaxel in Second Line (2L) Treatment of Metastatic Castration Resistant Prostate Cancer: an Economic Evaluation in Sweden. 18th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PCN61, 18 May 2013.
Rights and permissions
About this article
Cite this article
Cost effectiveness of newer treatments for prostate cancer. PharmacoEcon Outcomes News 680, 4 (2013). https://doi.org/10.1007/s40274-013-0463-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0463-x